GlassScriptPhysician profile
Scott S Simecek
NPI 1104865765
$16,246.63
in general payments reported to CMS, 2019-2025
42 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,540 · 2020: $1,105 · 2021: $872 · 2022: $1,114 · 2023: $8,300 · 2024: $1,728 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $4,553 · Travel and Lodging: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $4,553.34 |
| Travel and Lodging | $1,062.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,146.05 | 2023-2024 | Da Vinci Surgical System, Ion |
| Astrazeneca Pharmaceuticals LP | $1,423.00 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,388.66 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $998.01 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $599.55 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $444.67 | 2019-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $399.08 | 2019-2025 | |
| Mylan Specialty L.P. | $385.37 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $309.17 | 2019-2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $297.10 | 2020-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $250.49 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $220.94 | 2019-2020 | |
| Insmed, INC. | $216.53 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $206.74 | 2021-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $195.49 | 2020-2025 | Glassia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $154.56 | 2020-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Paratek Pharmaceuticals, INC. | $152.45 | 2020-2025 | Nuzyra |
| Philips North America LLC | $130.74 | 2019-2024 | (Ak6) Vest Therapy, (8874) Incourage |
| Viatris Specialty LLC | $108.15 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $107.48 | 2023-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $101.98 | 2019-2025 | Keytruda, Recarbrio, Zerbaxa |
| Ethicon INC. | $98.98 | 2020 | |
| Resmed Corp | $95.36 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $94.56 | 2020-2023 | Ultomiris |
| Arbor Pharmaceuticals, INC. | $91.74 | 2019-2022 | |
| Baxter Healthcare | $75.52 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $75.14 | 2019-2024 | Smartvest |
| Mallinckrodt Enterprises LLC | $64.92 | 2019 | |
| Genentech USA, INC. | $53.76 | 2019 | |
| Circassia INC. | $49.38 | 2019 | |
| Advanced Respiratory, INC | $41.96 | 2019-2021 | |
| Verona Pharma, INC. | $40.75 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $34.33 | 2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $33.39 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.56 | 2022 | |
| Inspire Medical Systems, INC. | $24.11 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $20.74 | 2019 | |
| Azurity Pharmaceuticals, INC. | $20.48 | 2024 | Horizant |
| Inogen, INC. | $19.10 | 2022 | |
| Amgen INC. | $19.02 | 2024 | Tavneos |
| Pfizer INC. | $14.09 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Simecek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.